Background: Fentanyl–midazolam remains a common analgosedation regimen for mechanically ventilated patients in many intensive care units (ICUs). Its adverse drug reactions (ADRs) may prolong ICU length of stay (LOS), but evidence is limited, particularly in Indonesia. Objective: To describe suspected ADRs associated with fentanyl–midazolam and their association with ICU LOS in mechanically ventilated patients. Methods: This retrospective cohort study reviewed records of adults receiving mechanical ventilation and continuous fentanyl–midazolam infusion in the ICU of an Indonesian academic hospital from January 2022 to April 2023. Of 460 patients screened, 80 were analyzed (40 with and 40 without suspected ADRs). Causality was assessed with the World Health Organization–Uppsala Monitoring Centre system and severity with the Hartwig scale. Prolonged LOS was defined as ≥3 days. Associations were tested with the chi-square test and expressed as risk ratios (RRs). Results: Among the 40 patients with suspected ADRs, the most frequent reactions were bradypnea (17/40, 42.5%), bradycardia (14/40, 35.0%), and apnea (4/40, 10.0%). Causality was probable in 27 patients (67.5%) and possible in 13 (32.5%), and 36 reactions (90.0%) were Hartwig level 1. Prolonged LOS occurred in 32 of 40 patients (80.0%) with ADRs and 22 of 40 (55.0%) without ADRs (p = 0.017; RR 1.45; 95% CI 1.06–2.00). Conclusion: Suspected fentanyl–midazolam ADRs, mostly mild respiratory depression and bradycardia, were associated with prolonged ICU stay. Close respiratory and hemodynamic monitoring and careful dose titration are warranted.